WebFeb 15, 2024 · Cytokinetics: In January 2024, Royalty Pharma acquired a royalty interest in aficamten from Cytokinetics for $150 million, including $50 million upfront, and two additional $50 million payments conditional upon the initiation of potential pivotal clinical trials for oHCM and non-obstructive hypertrophic cardiomyopathy. WebCytokinetics is dedicated to the discovery, development and commercialization of a novel class of therapeutics resulting from its leadership position in the emerging field of cytoskeletal pharmacology. Use the CB Insights Platform to explore Cytokinetics's full profile. ... Cytokinetics' R&D efforts aim to address pharmaceutical needs in cancer ...
Royalty Pharma - Investments, Portfolio & Company Exits
WebFeb 2, 2024 · Cytokinetics sold to Royalty Pharma a 4.5 percent royalty on potential worldwide sales of omecamtiv mecarbil for $90 million in an upfront cash payment. The royalty rate purchased may increase up to an additional 1 percent under certain circumstances. In addition, Royalty Pharma has agreed to purchase $10 million of … WebJan 7, 2024 · Per the terms, Royalty Pharma ( RPRX) will provide up to $300M for Cytokinetics ( CYTK) to support future commercialization of omecamtiv mecarbil and further development of aficamten and... borescope olympus iplex
Cytokinetics: Temper Your Expectations Of Aficamten …
WebJan 7, 2024 · Per the terms, Royalty Pharma ( RPRX) will provide up to $300M for … WebAs an investor, I've closely followed Ionis Pharmaceuticals, Inc. for over 15 years. So, it is personally very exciting that we announced today a significant… WebFeb 2, 2024 · Royalty Pharma Buys 4.5 Percent Royalty on Worldwide Sales for $90 … havant gov council tax